1359. Activity of Meropenem/Nacubactam Combination Against Gram-Negative Clinical Isolates: ROSCO Global Surveillance 2017
Sign Up to like & getrecommendations! Published in 2018 at "Open Forum Infectious Diseases"
DOI: 10.1093/ofid/ofy210.1190
Abstract: Abstract Background Nacubactam (NAC, OP0595, RG6080) is a novel member of the diazabicyclooctane inhibitor family with a dual mode of action, acting as a β-lactamase inhibitor and an antibacterial agent by means of PBP2 inactivation.… read more here.
Keywords: innovation center; mem nac; roche innovation; center basel ... See more keywords